Biomarkers in Oncology – Access & Reimbursement – Access & Reimbursement – Biomarkers in Oncology – Biomarker-Driven Prescribing in NSCLC, Colorectal Cancer, Breast Cancer (US)
The increasing focus on biomarkers has reshaped the treatment paradigm in oncology, allowing physicians to tailor treatments to subpopulations of patients diagnosed with breast cancer, NSCLC and colorectal cancer. As a result, treatment has become more targeted, with guidelines and payer policies updated to reflect the latest science, driving certain therapies like Merck & Co. Keytruda, Bristol-Myers Squibb’s Opdivo, AstraZeneca’s Imjudo and others powerhouse status in oncology. Although biomarker-driven therapies offer the advantage of selecting the patients most likely to respond to targeted therapy, they are typically premium-priced and subject to payer restrictions and cost-containment strategies. Identifying the barriers that influence the coverage and uptake of biomarker-driven therapies is key to a successful market strategy.
QUESTIONS ANSWERED
- What factors most influence payers’ reimbursement decisions about biomarker-driven therapies in NSCLC, colorectal cancer, and breast cancer?
- Do access and reimbursement challenges differ by indication, and how well established are biomarkers in each indication?
- Which payer-imposed utilization management controls most restrict oncologists’ prescribing of biomarker-driven therapies?
- What are payers’ opinion of emerging agents, and how will oncologists’ prescribing patterns change with the launch of new therapies?
